Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
38
self-reported 11–50 band
Founded
2007
19 years
Legal entities
1
ACRA
Office countries
1
1 address
Funding rounds
3
Series unknown · May 2025 · US$ 8.5M
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
BIOBOT SURGICAL PTE. LTD.Entity record →
UEN200715783Z
Legal entities
Show as table · Biobot Surgical: 1 registry entity
| BIOBOT SURGICAL PTE. LTD. | UEN 200715783Z |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
At Biobot Surgical, our mission is to revolutionize the realm of robotic-assisted biopsy and treatment for prostate cancer. As the landscape for prostate cancer treatment evolves, we aren’t just riding this wave of change — we’re propelling it, ushering in a new era of excellence in prostate disease management.
At the forefront of these advances in the standard of care in prostate cancer management, we are poised to address the global unmet need for a precise approach to transperineal procedures — and make a monumental impact on the lives of patients. Our first- and best-in-class surgical robot iSR’obot Mona Lisa has obtained key regulatory approvals, including Europe (CE mark), the US (FDA), Australia (TGA), and Singapore (HSA), and is being used in some of the most prestigious hospitals around the world.
We remain committed to advancing innovation in the field of robotic-assisted transperineal biopsy and treatment, and delivering the precision urologists require—and patients deserve.
Specialties
All 6 specialties
- Urology
- Prostate Cancer
- Robotic Surgery
- minimally-invasive
- Prostate Biopsy
- Prostate Diagnosis
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
Addresses
- SG79 Ayer Rajah Crescent; 04-05; Singapore, 139955Primary
Grid intelligence Members
Funding
Last round · 15 May 2025US$ 8.5MSeries unknown
Rounds3
Round typeSeries unknown · venture round
Amount (USD)8,500,000
Stage ranknot recorded
Investors named0
Since last round8 mo
Funding
Show as table · 3 funding rounds
| Rounds | 3 |
|---|---|
| Axis | 2007 to 2026 |
| Series unknown · 15 May 2025 | US$ 8.5M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Biobot Surgical?
One Singapore entity on ACRA. BIOBOT SURGICAL PTE. LTD. (UEN 200715783Z), high confidence.
How many people work at Biobot Surgical?
The record holds 38 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Biobot Surgical have offices?
One address on record, Singapore only. Primary: 79 Ayer Rajah Crescent, 04-05, Singapore 139955.
Has Biobot Surgical raised funding?
Three rounds. Latest 15 May 2025: Series unknown, US$8,500,000.
What does Biobot Surgical list as its specialties?
Six tags on the brand's own list, among them urology.
Which companies are listed alongside Biobot Surgical?
16 profiles list Biobot Surgical as a peer — 94th percentile in Medical Device. It lists ten peers of its own. Vivo Surgical and Biorithm list it back.